PAX2, PAX8, and PR are correlated with ovarian seromucinous borderline tumor with endometriosis

Bo Seong Yun1, Seyeon Won2, Ju-Hyun Kim3, Nara Lee2, Miseon Kim2, Mi Kyung Kim2, Mi-La Kim2, Yong Wook Jung2, Ji Young Kim4, Seok Ju Seong2 and Eunah Shin5*

Abstract

Background: Ovarian “seromucinous carcinoma” has been recently removed in 2020 5th Edition of WHO classification of Female Genital Tumors and is considered as a subtype of endometrioid carcinoma with mucinous differentiation, while “seromucinous borderline tumor” remains and exists as a distinct entity. Both diseases may be considered as no more same lineage. However, ovarian seromucinous borderline tumor (SMBT) is also one of the endometriosis-related neoplasm of ovary similar to endometrioid tumor, featuring that about 50% of ovarian SMBTs combine endometriosis. The present study was aimed to investigate whether the ovarian SMBTs are different in clinical features and molecular patterns, according to the presence of combined endometriosis.

Results: There were no statistical differences in clinical findings between two groups. There was also no significant difference in pregnancy outcomes and recurrence between two groups. In immunohistochemical patterns, there was a statistically significant difference in PAX2 and PAX8 expression between in ovarian SMBT with or without endometriosis ($P = 0.016$, $P < 0.001$). Only a few cases of ovarian SMBT with endometriosis showed expression of PAX2 and conversely, most of the cases showed expression of PAX8. PR positivity was more prominent in ovarian SMBT with endometriosis than without endometriosis ($P = 0.018$), although there was no difference in positive ER expression. There were no statistical differences in WT1, CK20 and CDX2 expressions between two groups.

Conclusions: Ovarian SMBT with endometriosis did not clinically differ from that without endometriosis. However, the molecular patterns were different between two groups and ovarian SMBT with endometriosis is close to endometrioid tumor types unlike SMBT without endometriosis. Further, a direct comparison study between seromucinous borderline tumor and endometrioid borderline tumor is needed with a gene profiling study to prove their relationship.

Keywords: Borderline tumor, Seromucinous, Endometrioid, Endometriosis, PAX2, PAX8, PR

*Correspondence: eunahshin@daum.net
5 Department of Pathology, Yongin Severance Hospital, Yonsei University College of Medicine, 363, Dongbaekjukjeon-daero, Giheung-gu, Yongin-si 16995, Gyeonggi-do, Korea

Full list of author information is available at the end of the article
a different proportion [1]. In the past, it has been classified under the ovarian mucinous tumor as endocervical-like type [2]. However, it has papillary projections within the cyst, which is mostly unilocular, and microscopically it shows characteristic broad papillae lined by serous type epithelial cells with abundant eosinophilic cytoplasm admixed with a varying number of endocervical-like mucinous cells [3]. Moreover, it shows a very different clinical course from GI type mucinous borderline tumor, rendering reclassification of the tumor as an independent category from the mucinous tumor.

SMBT has some distinctively characteristic features. First, endometriosis is found in about 50% of ovarian SMBTs, unlike other types of borderline tumors. SMBT is considered as one of the endometriosis-related neoplasm of the ovary, although the underlying causal relationship between the two is not elucidated. Second, the seromucinous category of the ovarian epithelial tumors no longer has carcinoma counterpart in WHO classification. Recently, ovarian “seromucinous carcinoma” has been removed from the seromucinous category in 2020 5th Edition of WHO classification of Female Genital Tumors, because its diagnostic reproducibility is poor and has a high proportion of molecular overlap with endometrioid carcinoma [4]. So instead, ovarian seromucinous carcinoma was removed from the seromucinous category and placed in endometrioid category as a subtype of endometrioid carcinoma with mucinous differentiation, while benign and borderline seromucinous tumors remains as a distinct entity.

Ovarian SMBTs consist of various cells of Mullerian origin and they also contain endometriosis in about 50%. However, little is known about the characteristics of ovarian SMBT and the reason for endometriosis-associated SMBT cases remains unknown. Therefore, we aimed to clarify whether the presence or absence of endometriosis in ovarian SMBTs show different characteristics, and thus validate the relationship between SMBT and endometriosis. There is scarce evidence exploring whether SMBTs differ clinically and molecularly according to the presence or absence of combined endometriosis.

We aimed to investigate whether the ovarian SMBTs are different in clinical features and histopathologic findings, according to the presence or absence of combined endometriosis. We used seven histologic markers (PAX2, PAX8, ER, PR, WT1, CK20 and CDX2) commonly expressed in other types of ovarian tumors such as serous, mucinous or endometrioid.

**Results**

**Comparison of clinicopathologic features according to combined endometriosis**

Clinical features were compared between SMBT with and without endometriosis in Table 1. There were no statistical differences in clinical findings between two groups.

The median follow-up period was 29 months (range 12.5–60.5 months). During the follow-up period, a total nine of 57 (15.8%) women who performed fertility sparing surgery were pregnant and delivered the live baby. There was no significant difference in pregnancy outcome between SMBT with and without endometriosis (Table 1).

Three patients had SMBT recurrence, which was confirmed by surgery. All three patients with recurrence were seen in only ovarian SMBT with endometriosis, although there was no the statistical significance. The death in all patients was not shown during the follow-up period. There was no significant difference in progression-free survival (PFS) or overall survival (OS) between two groups (Table 1).

**Comparison of immunohistochemical features according to combined endometriosis**

Representative photomicrographs of PAX2, PAX8, ER, and PR expression in SMBT with and without endometriosis were shown in Fig. 1.

There was a difference in PAX2 and PAX8 expression between in ovarian SMBT with or without endometriosis. Eleven of 22 (50.0%) patients without endometriosis showed positive PAX2 expression, while eight of 36 (22.2%) patients with endometriosis showed positivity ($P=0.016$). In contrast, all patients with endometriosis showed positive PAX8 expression, whereas only 14 of 22 (63.6%) patients without endometriosis showed positivity ($P<0.001$) (Table 2).

PR positivity was more prominent in ovarian SMBT with endometriosis than without endometriosis (72.2% vs. 40.9%, $P=0.018$), although there was no difference in positive ER expression. WT1, CK20 and CDX2 were scarcely expressed and were not different between ovarian SMBT with and without endometriosis (Table 2).

PAX2, PAX8, and PR expression in endometrioid borderline tumor (EBT) was also represented in Fig. 1. Their expressions in SMBT with endometriosis were similar to EBT unlike SMBT without endometriosis, although it was difficult to show the statistical significance due to small number of EBTs.

**Discussion**

Since the seromucinous tumor has been adopted in 2014 WHO classification of ovarian tumor, the “seromucinous carcinoma” part was changed to the variant of endometrioid carcinoma in 2020 WHO classification [4]. However, the “seromucinous borderline tumor” part is still in the distinct category
from “seromucinous carcinoma,” so two diseases may be considered as no more same lineage. SMBT has been one of the endometriosis-related ovarian tumors (EROT) similar to ovarian clear cell carcinoma and endometrioid carcinoma, while clear cell borderline tumor or endometrioid borderline tumor are very rare and are difficult to discuss whether both are representative tumor of EROT. In this study of total 162 patients

Table 1  Clinicopathologic features of patients with ovarian seromucinous borderline tumors with or without endometriosis

| Characteristics                        | All  (N=69) | Without endometriosis  (N=29) | With endometriosis  (N=40) | P value |
|----------------------------------------|-------------|-------------------------------|---------------------------|---------|
| Age (yrs)                              | 35.0 (30.0–43.0) | 33.0 (30.0–44.5) | 35.0 (30.2–41.5) | 0.889   |
| BMI (kg/m²)                            | 20.7 (19.1–22.3) | 20.9 (19.4–23.2) | 20.5 (18.8–22.2) | 0.508   |
| Nulliparous                            | 45 (65.2) | 19 (65.5) | 26 (65.0) | 0.964   |
| Menopause                              | 9 (13.0) | 4 (13.8) | 5 (12.5) | 1.000   |
| Borderline op history                   | 7 (10.1) | 3 (10.3) | 4 (10.0) | 1.000   |
| Endometriosis op history                | 3 (4.3) | 0 (0) | 3 (7.5) | 0.258   |
| ART history                            | 4 (5.8) | 2 (6.9) | 2 (5.0) | 1.000   |
| **Tumor and treatment**                 |             |                               |                           |         |
| Serum CA125 (U/ml)                      | 37.9 (17.6–62.9) | 30.0 (17.1–56.5) | 39.6 (17.3–63.6) | 0.586   |
| Normal                                 | 28 (44.4) | 14 (53.8) | 14 (37.8) | 0.208   |
| Elevated                               | 35 (55.6) | 12 (46.2) | 23 (62.2) | 0.894   |
| Tumor size (cm)                         | 6.3 (4.5–8.3) | 6.0 (4.1–9.5) | 6.3 (4.6–8.2) | 0.302   |
| Surgical method                         |             |                               |                           |         |
| Laparoscopy                            | 65 (94.2) | 26 (89.7) | 39 (97.5) | 0.620   |
| Laparotomy                             | 4 (5.8) | 3 (10.3) | 1 (2.5) | 0.863   |
| **Tumorectomy method**                  |             |                               |                           |         |
| Cystectomy                             | 19 (27.5) | 9 (31.0) | 10 (25.0) | 0.643   |
| USO                                    | 38 (55.1) | 14 (48.3) | 24 (60.0) | 0.154   |
| TH with BSO                            | 12 (17.4) | 6 (20.7) | 6 (15.0) | 0.634   |
| Staging operation                      |             |                               |                           |         |
| Not done                               | 23 (33.3) | 10 (34.5) | 13 (32.5) | 0.288   |
| Comprehensive                          | 46 (66.7) | 19 (65.5) | 27 (67.5) | 0.278   |
| Stage                                  |             |                               |                           | 0.167   |
| 1A                                     | 29 (42.0) | 11 (37.9) | 18 (45.0) | 0.625   |
| 1B                                     | 3 (4.3) | 3 (10.3) | 0 (0) | 0.258   |
| 1C                                     | 36 (52.2) | 15 (51.7) | 21 (52.5) | 0.831   |
| 2B                                     | 1 (1.4) | 0 (0) | 1 (2.5) | 1.000   |
| Bilaterality of borderline tumor       | 5 (7.2) | 3 (10.3) | 2 (5.0) | 0.643   |
| Capsule involvement                    | 5 (7.2) | 4 (13.8) | 1 (2.5) | 0.154   |
| Intraepithelial carcinoma              | 4 (5.8) | 1 (3.4) | 3 (7.5) | 0.634   |
| Microinvasion                          | 9 (13.0) | 4 (13.8) | 5 (12.5) | 1.000   |
| Non- invasive implant                   | 1 (1.4) | 0 (0) | 1 (2.5) | 1.000   |
| Peritoneal cytology                    | 4 (10.8) | 2 (14.3) | 2 (8.7) | 0.625   |
| Pelvic adhesion                        | 19 (27.5) | 6 (20.7) | 13 (32.5) | 0.278   |

**Outcomes**

| Pregnancy outcome                      | 9 (15.8) | 2 (8.7) | 7 (20.6) | 0.288   |
| Recurrence of borderline tumor         | 3 (4.3) | 0 (0) | 3 (7.5) | 0.258   |
| PFS, month                             | 28.0 (12.5–60.0) | 29.0 (11.5–60.0) | 28.0 (12.5–61.0) | 0.860   |
| OS, month                              | 29.0 (12.5–65.0) | 29.0 (11.5–60.0) | 28.0 (12.5–66.2) | 0.831   |

Data were shown as median and interquartile ranges or numbers (percentages)

EMI endometriosis, BMI body mass index, ART assisted reproductive technology, USO unilateral salpingo-oophorectomy, TH total hysterectomy, BSO bilateral salpingo-oophorectomy, LND lymph node dissection, PFS progression-free survival, OS overall survival

...
who underwent surgical excision of the ovarian borderline tumor between January 2009 and January 2020 at a single institution, only two patients were diagnosed as EBT, and there was no clear cell borderline tumor. Meanwhile, SMBT were diagnosed in 69 patients (42% of all borderline tumors), and 58% of SMBT were found with combined endometriosis.

This study showed that there was no difference in clinical features of ovarian SMBT according to the combined endometriosis, which may be postulated to be due to the fact that they are all borderline tumors. The presence or absence of endometriosis cannot be defining factors to have an impact on clinical outcomes. But it should be noted that, although there was no statistical significance,
Table 2  Immunohistochemical features in ovarian seromucinous borderline tumors with or without endometriosis

| Positive Expression | Without endometriosis (N=22) | With endometriosis (N=36) | P value |
|---------------------|-------------------------------|---------------------------|---------|
| PAX2                | 11 (50.0)                    | 8 (22.2)                  | 0.029   |
| PAX8                | 14 (63.6)                    | 36 (100.0)                | <0.001  |
| ER                  | 18 (81.8)                    | 33 (91.7)                 | 0.409   |
| PR                  | 9 (40.9)                     | 26 (72.2)                 | 0.018   |
| WT1                 | 8 (36.4)                     | 8 (22.2)                  | 0.242   |
| CK20                | 0 (0)                        | 1 (2.8)                   | 1.000   |
| CDX2                | 0 (0)                        | 1 (2.8)                   | 1.000   |

Data were shown as numbers (percentages)

all three recurred cases were SMBT with endometriosis. Even serum CA125, endometriosis operation history, or history of assisted reproductive technology (ART), which are known as typical endometriosis features, were not different. Fertility sparing surgery was performed in 82% of patients with ovarian SMBT including even cystectomy in 27% of patients, because most women were still young, whose median age was 35 years. The median age of SMBT in this study was slightly younger than in other literatures, which showed more late reproductive ages as 45–47 years [5, 6] or even 63.2 years [7]. However, these studies had relatively smaller number of cases than the present study, and large cohort of ovarian borderline tumor reported that the mean age was 36–38 years [8], similar to this study.

Pregnancy outcomes with live birth between two groups were not significantly different. This study precisely lacked the intention to conceive or the rate of abortion, but the real live birth outcomes was suggested in fertility sparing surgery group regardless of effort for pregnancy. Approximately 15% women with fertility sparing surgery normally delivered, and 20% women with combined endometriosis had live birth, which was slightly higher than the no endometriosis group, although there was no statistical significance. In all types of borderline tumor, it was reported that about 42% of live birth rate after fertility sparing surgery and 90.7% were free of recurrence [9].

Recently, new Müllerian markers (PAX2 and PAX8) are reported as useful markers to differentiate Müllerian mucinous tumors from non-Müllerian tumors [10–12]. PAX2 and PAX8 belong to the pair box gene family consisting of nine members (PAX1 to PAX9), each of which encodes a transcription factor [11]. These are expressed during fetal development and known to control the development of organs deriving from the Müllerian duct such as the fallopian tube, endometrium, and endocervix, but not the development of the ovary [13, 14]. In our study, a few cases of SMBT with combined endometriosis showed positive expression of PAX2 and most cases showed positive expression of PAX8 in contrast to SMBTs without endometriosis. In ovarian tumors, PAX2 is detected in clear cell and mucinous tumors, but absent in most endometrioid tumors [15–17], while PAX8 shows high expression in clear cell and endometrioid tumors and reduced expression in mucinous tumors [18–20]. In the same seromucinous tumor category, there was no uniform pattern in PAX2 and PAX8 expression. However, when the seromucinous tumor was divided according to the presence or absence of endometriosis, a unique expression pattern was shown.

SMBT with endometriosis in this study showed similar expression patterns of PAX2 and PAX8 with those in endometrioid tumors, in contrast to SMBT without endometriosis. The exact mechanism explaining how endometriosis is related to the development or progression of ovarian SMBT is not clarified yet, however, it has become clear that Müllerian markers such as PAX2 and PAX8 show distinctively different expression pattern between SMBTs with and without endometriosis. In this study, PAX2 and PAX8 patterns in two patients with EBT was seen. PAX2 and PAX8 expressions in SMBT with endometriosis were closer to the expression patterns in EBT, implicating that SMBT with endometriosis might also be associated with endometrioid tumors like ex-“seromucinous carcinoma” and may be different from SMBT without endometriosis in a specific molecular pattern.

Highly positive ER expression was found in both SMBT with and without endometriosis. In contrast, PR expression was higher in SMBT with endometriosis than without endometriosis. Other literature reported that both ER and PR positivity were shown in SMBT, while negative for ER and PR in mucinous borderline tumor [21]. In a recent study, hormone receptor expression, especially PR expression, is most common in endometrioid tumors but almost absent in clear call and mucinous carcinomas [22, 23]. PR patterns of ovarian SMBT with endometriosis in this study is also close to EBTs, suggesting ovarian SMBT with endometriosis may be a part of endometrioid tumors unlike SMBT without endometriosis.

The Wilms tumor 1 (WT1) gene was discovered as a tumor suppressor gene in Wilms tumor [24]. In gynecology, WT1 expression has been used for diagnostic purposes of serous type tumors [25]. Both CK20 and CDX2 were expressed in mucinous tumors, and commonly used for distinguish metastatic ovarian mucinous tumors from primary ovarian mucinous tumors [26]. Ovarian SMBT in this study showed no or low expression of all serous
and mucinous markers, which means that SMBTs are not close to serous or mucinous characteristics.

A limitation of this study was the narrow cohort, which was only confined to a single institution. In addition, no scoring system was used for the interpretation of immunohistochemical staining, which was not delicate. The other of limitation is that this is not the direct comparison study between ovarian SMBT and EBT, due to the rarity of EBT. However, this study discussed the findings of larger numbers of ovarian SMBTs than other literature, and it can conclude the more objective features of these tumors.

In conclusion, only a few cases of ovarian SMBT with endometriosis showed expression of PAX2 and conversely, most of the cases of ovarian SMBTs with endometriosis showed expression of PAX8 in contrast to SMBTs without endometriosis. PR positivity was also more prominent in ovarian SMBT with endometriosis than without endometriosis. Ovarian SMBT with endometriosis showed the similar immunohistochemical patterns to endometrioid tumors unlike SMBT without endometriosis even though SMBT with endometriosis and without endometriosis have same clinical patterns. It suggests that just as seromucinous carcinoma has been removed from the seromucinous category and newly defined as a subtype of endometrioid carcinoma, SMBT with endometriosis may also be a borderline counterpart of seromucinous carcinoma, and may have to be removed from the seromucinous category and put under the endometrioid borderline category as a subtype. To validate this hypothesis, further comparison studies between seromucinous borderline tumor and endometrioid tumor are needed with gene profiling studies to prove their relationship.

Methods

Tumors and patients

This retrospective study was approved by the institutional review board (IRB) of CHA Gangnam Medical Center (No. GCI 2020–04–010–001) and conducted in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived by the IRB due to its retrospective design.

Patients who underwent surgical excision of ovarian borderline tumors between January 2009 and January 2020 at CHA Gangnam Medical Center were identified and selected for review. A total of 162 patients underwent surgical excision of the ovarian borderline tumor in this period. In accordance with the new 2014 WHO classification of ovarian tumors, hematoxylin- and eosin-stained slides of all selected cases were reviewed by two pathologists, and all patients were reclassified according to the criteria. Two of 26 patients with ovarian serous borderline tumor were confirmed as SMBT and 17 of 84 patients with ovarian mucinous borderline tumor were diagnosed as SMBT. The two EBTs were confirmed to be the same type. Finally, 69 of 162 patients with borderline tumors were diagnosed as having ovarian SMBT and was included in the analysis, 40 of whom (58.0%) with ovarian SMBT showed combined endometriosis and 29 did not.

Clinical information of patients was obtained from medical records. Clinical information on age, body mass index, parity, pre-/post-menopause, history of ovarian borderline tumor surgery, history of ovarian endometriosis surgery, history of ART, serum CA125 levels (normal range: 0–35 U/mL), and tumor size by ultrasonography were evaluated. Surgical method was laparoscopy or laparotomy. Tumorectomy method was cystectomy, unilateral salpingo-oophorectomy or total hysterectomy with bilateral salpingo-oophorectomy. Staging operation was divided as not done or comprehensive surgical staging (including omentectomy, appendectomy, peritoneal biopsy, peritoneal cytology or lymph node dissection). Staging was re-evaluated by 2014 International Federation of Gynecology and Obstetrics system. The presence of tumor in contralateral ovary was also evaluated, and the tumor type was divided into borderline, benign or endometrioma. The presence of capsule involvement, histologic presence of intraepithelial carcinoma or micro-invasion, the presence of peritoneal implant, positivity of peritoneal cytology, and pelvic adhesion of operative field were evaluated.

After surgery, the presence of pregnancy and the recurrence of borderline tumor or carcinoma were evaluated. PFS was defined as the period from the day of first surgery to the day of recurrence. OS was defined as the period from the day of first surgery to that of last contact alive.

Tissue microarray construction

Tissue microarray (TMA) was constructed in 58 of 69 (84.1%) patients with ovarian SMBT due to the issues with the quality of paraffin block, and also in two patients with EBT. Representative areas were selected on a hematoxylin- and eosin-stained slide of each case, and corresponding areas on the matching paraffin block were marked. Using a manual device, three 2 mm-sized cores from representative areas of each case were punched from the donor block and transferred to the 6 × 10 recipient block.

Immunohistochemistry

Only 3 μm thick tissue sections of each TMA block were cut, deparaffinized and rehydrated in xylene, and graded alcohol. Ventana Discovery XT automated stainer (Ventana Medical Systems, Tucson, AZ, USA) was used for
immunohistochemical staining. Primary antibodies used were as follows: PAX2 (Abcam, USA), PAX8 (Roche, Switzerland), ER (Novocastra, England), PR (Novocastra, England), WT-1 (Novocastra, England), CK20 (Dako, Denmark) and CDX2 (Cell marque, USA).

**Interpretation of immunohistochemical staining**

Epididymis tissue was used as a positive control for PAX2 and kidney tubules as a positive control for PAX8. Invasive ductal carcinoma of the breast with Allred score 8 for ER and PR was used as positive controls for ER and PR staining. Mesotheloma tissue was used as a positive control for WT-1, and colon cancer tissue was used as a positive control for both CK20 and CDX2. Each IHC staining intensity was graded at first as follows: complete negative, 0; weak staining, 1+; moderate, 2+; and strong, 3+, as in invasive ductal carcinoma of the breast. However, most of the cases that stained positive were grade 2 or 3 and thus grading was of little significant value. The cases were instead subgrouped into positive or negative staining groups.

**Statistical analysis**

The numerical variables were presented as the median and interquartile range after checking the Kolmogorov–Smirnov normality test. The differences of the groups were evaluated using the Mann–Whitney test for continuous variables, the $\chi^2$ test was used. $P$ value < 0.05 was considered statistically significant. The statistical analysis was performed using SPSS ver. 26.0 (IBM Corp., Armonk, NY, USA).

**Abbreviations**

SMBT: Seromucinous borderline tumor; EBT: Endometrioid borderline tumor; PFS: Progression-free survival; OS: Overall survival; EORT: Endometriosis-related ovarian tumors; ART: Assisted reproductive technology; IRB: Institutional review board; TMA: Tissue microarray.

**Acknowledgements**

We sincerely thank all of Women’s Healthcare Center, and CHA Medical Center, CHA University who are involved in this study.

**Authors’ contributions**

BSY: Development of methodology and performing the experiments, and data analysis; writing of the original manuscript draft. SW: Collection of data, management of dataset and formal data analysis. JK: Selection of patients and clinical outcome validation. NL: Formulation of research ideas and aims, research process and data analysis. MK: Formulation of research ideas and aims, research process, data analysis and critical review and revision of the manuscript. MK (Mi-La Kim): Collection of data, management of dataset and formal data analysis. YWJ: Development of methodology, and critical review and revision of the manuscript. JYK: Histopathology study of tumor samples. SJS: design of methodology, critical review and revision of the manuscript, coordination of research activity. ES: Formulation of research ideas and aims, design of methodology, critical review and revision of the manuscript, coordination of research activity. All authors read and approved the final manuscript.

**Funding**

This research was supported by a faculty research grant from Yonsei University College of Medicine for 2020 (Grant No. 6–2020-0135).

**Availability of data and materials**

The dataset used and/or analyzed during the current study are available from the corresponding authors on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

This study has been approved by the institutional review board (IRB) of CHA Gangnam Medical Center (No. GCI 2020-04-010-001) and conducted in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived by the IRB due to its retrospective design.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no competing interests.

**Author details**

1. Department of Obstetrics and Gynecology, CHA Ilsan Medical Center, CHA University School of Medicine, Goyang, Korea. 2. Department of Obstetrics and Gynecology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea. 3. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. 4. Department of Pathology, CHA Gangnam Medical Center, CHA University School of Medicine, Seoul, Korea. 5. Department of Pathology, Yongin Severance Hospital, Yonsei University College of Medicine, 363, Dongbaekjukjeon-daero, Gifueung-gu, Yongin-si 16955, Gyeonggi-do, Korea.

Received: 14 August 2021   Accepted: 30 March 2022

Published online: 06 April 2022

**References**

1. Köbel M, Bell DA, Carcangiu ML, Oliva E, Prat J, Shih IM, et al. WHO classification of tumours of female reproductive organs: seromucinous tumors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, et al., editors. World Health Organization. Lyon: International Agency for Research on Cancer, 2014. p. 38–40.

2. Rutgers JL, Scully RE. Ovarian mullerian mucinous papillary cystadenomas of borderline malignancy. A clinicopathologic analysis. Cancer. 1988;61:340–8.

3. Kurman RJ, Shih IM. Seromucinous tumors of the ovary: What’s in a name? Int J Gynecol Pathol. 2016;35:78–81.

4. Köbel M, Kim K-R, McCluggage WG, Shih I, Single N, et al. Seromucinous carcinoma. In: Cheung AN, Ellerson LH, Gilks CB, Kim K-R, Kong CS, Lax SF, Longacre TA, et al., editors. Tumors of ovary. In WHO Classification of Female Genital Tumors, vol. 70. 5th ed. Lyon: Edited by the WHO Classification of Tumors Editorial Board, International Agency for Research on Cancer (IARC), 2020.

5. Shappell HW, Ropiel MA, Smith Sehdev AE, Ronnett BM, Kurman RJ. Diagnostic criteria and behavior of ovarian seromucinous (endocervical-type mucinous and mixed cell-type) tumors: atypical proliferative (borderline) tumors, intraepithelial, microinvasive, and invasive carcinomas. Am J Surg Pathol. 2002;26:1529–41.

6. Vang R, Gown AM, Barry TS, Wheeler DT, Ronnett BM. Ovarian atypical proliferative (borderline) mucinous tumors; gastrointestinal and seromucinous (endocervical-like) types are immunophenotypically distinctive. Int J Gynecol Pathol. 2006;25:83–9.

7. Rutgers JKL. Mullerian mucinous/mixed epithelial (Seromucinous) ovarian tumors. AJSP. 2016;21:206–13.

8. Li N, Gou J, Li L, Ming X, Hu TW, Li Z. Staging procedures fail to benefit women with borderline ovarian tumours who want to preserve fertility: a retrospective analysis of 448 cases. BMC Cancer. 2020;20:769.
9. Kumari S, Kumar S, Bhatla N, Mathur S, Thulkar S, Kumar L. Oncologic and reproductive outcomes of borderline ovarian tumors in Indian population. Gynecol Oncol Rep. 2021;36:1007–16.

10. Zhai QJ, Ozcan A, Hamilton C, Shen SS, Coffey D, Krishnan B, et al. PAX-2 expression in non-neoplastic, primary neoplastic, and metastatic neoplastic tissue: A comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2010;18:323–32.

11. Ozcan A, Liles N, Coffey D, Shen SS, Truong LD. PAX2 and PAX8 expression in primary and metastatic Mullerian epithelial tumors: a comprehensive comparison. Am J Surg Pathol. 2011;35:1837–47.

12. Ozcan A, Shen SS, Hamilton C, Arjana K, Coffey D, Krishnan B, et al. PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study. Mod Pathol. 2011;24:751–64.

13. Plotzke JM, Zhao R, Hrycaj SM, Harms PW, Mehra R, Chan MP. Immunohistochemical expression of PAX8, PAX2, and cytokeratin in melanomas. J Cutan Pathol. 2021;48:1246–51.

14. Li CG, Eccles MR. PAX Genes in Cancer; Friends or Foes? Front Genet. 2012;3:6.

15. Song H, Kwan SY, Iaguirre DI, Zu Z, Tsang YT, Tung CS, et al. PAX2 Expression in Ovarian Cancer. Int J Mol Sci. 2013;14:6090–105.

16. Tung CS, Mok SC, Tsang YT, Zu Z, Song H, Liu J, et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol. 2009;22:1243–50.

17. Tong GX, Chiriboga L, Hamele-Bena D, Borczuk AC. Expression of PAX2 in papillary serous carcinoma of the ovary: immunohistochemical evidence of fallopian tube or secondary Mullerian system origin? Mod Pathol. 2007;20:856–63.

18. Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32:1566–71.

19. Tacha D, Zhou D, Cheng L. Expression of PAX8 in normal and neoplastic tissues: a comprehensive immunohistochemical study. Appl Immunohistochem Mol Morphol. 2011;19:293–9.

20. Laury AP, Perets R, Piao H, Krane JF, Barletta JA, French C, et al. A comprehensive analysis of PAX8 expression in human epithelial tumors. Am J Surg Pathol. 2011;35:816–26.

21. Nagamine M, Mikami Y. Ovarian Seromucinous Tumors: Pathogenesis, Morphologic Spectrum, and Clinical Issues. Diagnostics (Basel). 2020;10:77.

22. Kobel M, Kallologer SE, Boyd N, McKinney S, Mehl E, Palmer C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PloS Med. 2008;5:e232.

23. Sieh W, Kobel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013;14:853–62.

24. Zhang Y, Yan WT, Yang ZY, Li YL, Tan XN, Jiang J, et al. The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism. Int J Biol Sci. 2020;16:1474–80.

25. Manu V, Heinz TA, Borah DJ, Srinivas V. Serous ovarian tumors: Immunohistochemical profiling as an aid to grading and understanding tumorigenesis. Med J Armed Forces India. 2020;76:30–6.

26. Shin JH, Bae JH, Lee A, Jung CK, Yim HW, Park JS, et al. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol. 2010;40:208–13.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.